XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Oct. 10, 2018
Jun. 14, 2018
Jan. 31, 2023
Nov. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Proceeds from warrant exercised         $ 0 $ 0 $ 425  
Employees Directors And Non Employees [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted average fair value of stock options granted         $ 0.7 $ 1.51 $ 3.81  
Aggregate intrinsic value of exercised options         $ 0 $ 19 $ 759  
Employee Stock Purchase Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Ordinary shares reserved for issuance         600,000      
Ordinary shares available for issuance         114,146      
Offering period         five months      
Percentage of use of base salary to purchase ordinary shares         15.00%      
Aggregate limit of ordinary shares per calendar year         $ 40      
Percentage of fair market value of ordinary shares at time of offering         85.00%      
Options granted         0 158,025 117,829  
2010 Share Option Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Ordinary shares reserved for issuance         13,895,152      
Ordinary shares available for issuance         1,202,301      
Vesting period         4 years      
Award expiration period         10 years      
Unrecognized share-based compensation expense         $ 5,370      
Unrecognized compensation cost, recognition period         2 years 21 days      
Warrant [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Warrants purchase to ordinary shares         0 0 3,955,696 3,955,696
Warrants purchase to ordinary shares remain outstanding         297,469 297,469    
Proceeds from warrant exercised             $ 18,750 $ 18,750
Master Clinical Agreement [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Offering price per share $ 4.95     $ 8.57333        
Maximum Authorized Proceeds From Issuance Of Common Stock $ 2,424,243     $ 2,332,815        
Equity investment $ 12,000     $ 20,000        
Percentage of closing price 33.00%     33.00%        
Collaborative Arrangements [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Maximum Authorized Proceeds From Issuance Of Common Stock         $ 7,788      
Issuance expenses         91      
Deferred Participation Of B M S In R And D Expenses         4,121      
Collaborative Arrangements Two [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Maximum Authorized Proceeds From Issuance Of Common Stock         14,958      
Issuance expenses         42      
Deferred Participation Of B M S In R And D Expenses         $ 5,000      
JMP Securities LLC [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Offering price per share   $ 3.95            
Warrants purchase to ordinary shares   4,253,165            
Exercise price of warrants   $ 4.74            
Expiration period of warrants   5 years            
Issuance of shares, net, shares   5,316,457            
Issuance expenses   $ 1,233            
Proceeds from ordinary shares in offering   $ 19,767            
Leerink Partners LLC [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Issuance of shares, net, shares         2,612,822      
Issuance expenses         $ 513      
Proceeds from ordinary shares in offering     $ 50,000   $ 3,081